CDLX Quote, Financials, Valuation and Earnings

Lendway has a net margin of -21.46% compared to Cardlytics's net margin of 3.61%. Cardlytics's return on equity of -145.45% beat Lendway's return on equity of -29.67%.

Cardlytics has a consensus price target of $2.54, signalling upside risk potential of 28.28%. On the other hand Lendway has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardlytics has higher upside potential than Lendway, analysts believe Cardlytics is more attractive than Lendway.

Cardlytics has a beta of 1.297, which suggesting that the stock is 29.698% more volatile than S&P 500. In comparison Lendway has a beta of 2.402, suggesting its more volatile than the S&P 500 by 140.225%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lendway offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Lendway pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $61.9M, which are larger than Lendway quarterly revenues of $12.4M. Cardlytics's net income of -$13.3M is lower than Lendway's net income of $449K. Notably, Cardlytics's price-to-earnings ratio is -- while Lendway's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.37x versus 0.20x for Lendway. Usually stocks with elevated PS ratios are considered overvalued.

Magnite has a net margin of -21.46% compared to Cardlytics's net margin of -6.19%. Cardlytics's return on equity of -145.45% beat Magnite's return on equity of 4.24%.

Cardlytics has a consensus price target of $2.54, signalling upside risk potential of 28.28%. On the other hand Magnite has an analysts' consensus of $19.19 which suggests that it could grow by 25.28%. Given that Cardlytics has higher upside potential than Magnite, analysts believe Cardlytics is more attractive than Magnite.

Cardlytics has a beta of 1.297, which suggesting that the stock is 29.698% more volatile than S&P 500. In comparison Magnite has a beta of 2.693, suggesting its more volatile than the S&P 500 by 169.283%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Magnite offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Magnite pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $61.9M, which are smaller than Magnite quarterly revenues of $155.8M. Cardlytics's net income of -$13.3M is lower than Magnite's net income of -$9.6M. Notably, Cardlytics's price-to-earnings ratio is -- while Magnite's PE ratio is 76.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.37x versus 3.39x for Magnite. Usually stocks with elevated PS ratios are considered overvalued.

Stagwell has a net margin of -21.46% compared to Cardlytics's net margin of -0.45%. Cardlytics's return on equity of -145.45% beat Stagwell's return on equity of 0.08%.

Cardlytics has a consensus price target of $2.54, signalling upside risk potential of 28.28%. On the other hand Stagwell has an analysts' consensus of $8.34 which suggests that it could grow by 60.64%. Given that Stagwell has higher upside potential than Cardlytics, analysts believe Stagwell is more attractive than Cardlytics.

Cardlytics has a beta of 1.297, which suggesting that the stock is 29.698% more volatile than S&P 500. In comparison Stagwell has a beta of 1.513, suggesting its more volatile than the S&P 500 by 51.292%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stagwell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Stagwell pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $61.9M, which are smaller than Stagwell quarterly revenues of $651.7M. Cardlytics's net income of -$13.3M is lower than Stagwell's net income of -$2.9M. Notably, Cardlytics's price-to-earnings ratio is -- while Stagwell's PE ratio is 249.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.37x versus 0.28x for Stagwell. Usually stocks with elevated PS ratios are considered overvalued.

Ziff Davis has a net margin of -21.46% compared to Cardlytics's net margin of 7.38%. Cardlytics's return on equity of -145.45% beat Ziff Davis's return on equity of 4.19%.

Cardlytics has a consensus price target of $2.54, signalling upside risk potential of 28.28%. On the other hand Ziff Davis has an analysts' consensus of $41.33 which suggests that it could grow by 25.86%. Given that Cardlytics has higher upside potential than Ziff Davis, analysts believe Cardlytics is more attractive than Ziff Davis.

Cardlytics has a beta of 1.297, which suggesting that the stock is 29.698% more volatile than S&P 500. In comparison Ziff Davis has a beta of 1.575, suggesting its more volatile than the S&P 500 by 57.466%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ziff Davis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Ziff Davis pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $61.9M, which are smaller than Ziff Davis quarterly revenues of $328.6M. Cardlytics's net income of -$13.3M is lower than Ziff Davis's net income of $24.2M. Notably, Cardlytics's price-to-earnings ratio is -- while Ziff Davis's PE ratio is 19.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.37x versus 1.05x for Ziff Davis. Usually stocks with elevated PS ratios are considered overvalued.